- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Javed Butler Discusses the Possibility of HFpEF Combination Treatment
Treatment for heart failure with preserved ejection fraction (HFpEF) may soon resemble that for heart failure with reduced ejection fraction (HFrEF), noted Javed Butler, MD, MPH, MBA, of the University of Mississippi.
Treatment for heart failure with preserved ejection fraction (HFpEF) may soon resemble that for heart failure with reduced ejection fraction (HFrEF), with empagliflozin and mineralocorticoid receptor antagonists (MRA) showing promise, noted Javed Butler, MD, MPH, MBA, chairman for the Department of Medicine at the University of Mississippi.
Transcript
What are your thoughts on a combination regimen for HFpEF that contains empagliflozin or an SGLT2 inhibitor as the anchor drug?
I completely agree with that mindset. That mindset we had, and we were successful in HFrEF, so nobody questioned what is the drug for HFrEF to give combination therapy. And if you now look at this, we now have data with empagliflozin for EF [ejection fraction] all the way up to 65%. We'll see what happens above 65% soon, but we know that valsartan/sacubitril with median EF of less than 57% showed benefit. If you exclude the Russia/Georgia data from TOPCAT and all the heterogeneity that we saw, MRA seems to be benefiting as well. And now, obviously, we have HFpEF trials going on with MRA.
I would say that the HFpEF treatment, or at least a segment of HFpEF treatment, will start looking very much like HFrEF. But certainly, with EMPEROR-Preserved, empagliflozin all the way up to 65% is pretty much a straightforward answer.
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
